Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: silInv who wrote (835)	7/26/1999 5:32:00 PM
From: opalapril	Read Replies (1) \| Respond to of 1906

It's a guess, but it looks like this was a correction to a press release insisted upon by the FDA to save the face of commissioners. Here's a plausible scenario: FDA staff said they will approve without additional P-3 and AMGN relied on that in producing the release, but everyone overlooked the fact commissioners have the final say. Will they go along if/when FDA staff recommends it? I expect so. It would be a rare event if they didn't.